Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
University of Washington
University of California, Davis
Dana-Farber Cancer Institute
MEI Pharma, Inc.
Academic and Community Cancer Research United
Altor BioScience
Ipsen
Swiss Cancer Institute
SecuraBio
SecuraBio
University of Nebraska
Washington University School of Medicine
University of Washington
Swiss Cancer Institute
MEI Pharma, Inc.
Medical College of Wisconsin
University of Southampton
Spectrum Pharmaceuticals, Inc
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Seagen Inc.
Gilead Sciences
Barbara Ann Karmanos Cancer Institute
Seagen Inc.
Gilead Sciences
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
The Lymphoma Academic Research Organisation
Pfizer
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Miami
Beth Israel Deaconess Medical Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
CTI BioPharma
National Cancer Institute (NCI)
Duke University
Janssen-Cilag G.m.b.H
Sanofi
Northside Hospital, Inc.
University of Alabama at Birmingham
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)